The Investor
02 Sep 2026, 15:36
Alnylam Pharmaceuticals Stock Jumps 8.5% as H.C. Wainwright Reiterates Buy Rating
Alnylam Pharmaceuticals (NASDAQ: ALNY) shares rose about 8.5% Wednesday after H.C. Wainwright reiterated its Buy rating on the biotechnology company, maintaining a $455 price target.
Analyst Patrick R. Trucchio reaffirmed the bullish rating as Alnylam shares traded around $266.94. The $455 target represents roughly 70% upside from that level, signaling substantial confidence in the company’s longer-term prospects.
Alnylam is a biotechnology company specializing in RNA interference, or RNAi, therapeutics, an approach designed to silence disease-causing genes. The company has built a commercial portfolio around the technology while continuing to develop treatments across several therapeutic areas.
The analyst action appears to have contributed to positive sentiment around the stock, with shares gaining 8.5%. The rating information provided does not include H.C. Wainwright’s specific reasoning for maintaining the Buy recommendation, so the precise factors behind the analyst’s valuation cannot be determined from the report alone.
Alnylam Pharmaceuticals (NASDAQ: ALNY) shares rose about 8.5% Wednesday after H.C. Wainwright reiterated its Buy rating on the biotechnology company, maintaining a $455 price target.
Analyst Patrick R. Trucchio reaffirmed the bullish rating as Alnylam shares traded around $266.94. The $455 target represents roughly 70% upside from that level, signaling substantial confidence in the company’s longer-term prospects.
Alnylam is a biotechnology company specializing in RNA interference, or RNAi, therapeutics, an approach designed to silence disease-causing genes. The company has built a commercial portfolio around the technology while continuing to develop treatments across several therapeutic areas.
The analyst action appears to have contributed to positive sentiment around the stock, with shares gaining 8.5%. The rating information provided does not include H.C. Wainwright’s specific reasoning for maintaining the Buy recommendation, so the precise factors behind the analyst’s valuation cannot be determined from the report alone.
